Alcon Inc (ALC)
79.57
+1.15
(+1.47%)
USD |
NYSE |
May 03, 16:00
79.57
0.00 (0.00%)
Pre-Market: 20:00
Alcon Price to Book Value: 1.903 for May 3, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 1.903 |
| May 02, 2024 | 1.876 |
| May 01, 2024 | 1.878 |
| April 30, 2024 | 1.855 |
| April 29, 2024 | 1.883 |
| April 26, 2024 | 1.884 |
| April 25, 2024 | 1.886 |
| April 24, 2024 | 1.903 |
| April 23, 2024 | 1.932 |
| April 22, 2024 | 1.928 |
| April 19, 2024 | 1.902 |
| April 18, 2024 | 1.877 |
| April 17, 2024 | 1.889 |
| April 16, 2024 | 1.904 |
| April 15, 2024 | 1.939 |
| April 12, 2024 | 1.944 |
| April 11, 2024 | 1.968 |
| April 10, 2024 | 1.966 |
| April 09, 2024 | 1.977 |
| April 08, 2024 | 2.005 |
| April 05, 2024 | 2.028 |
| April 04, 2024 | 2.000 |
| April 03, 2024 | 2.011 |
| April 02, 2024 | 1.954 |
| April 01, 2024 | 1.962 |
| Date | Value |
|---|---|
| March 28, 2024 | 1.992 |
| March 27, 2024 | 1.992 |
| March 26, 2024 | 1.976 |
| March 25, 2024 | 1.984 |
| March 22, 2024 | 2.000 |
| March 21, 2024 | 2.007 |
| March 20, 2024 | 2.023 |
| March 19, 2024 | 2.026 |
| March 18, 2024 | 2.012 |
| March 15, 2024 | 2.032 |
| March 14, 2024 | 2.055 |
| March 13, 2024 | 2.089 |
| March 12, 2024 | 2.108 |
| March 11, 2024 | 2.108 |
| March 08, 2024 | 2.087 |
| March 07, 2024 | 2.079 |
| March 06, 2024 | 2.051 |
| March 05, 2024 | 2.033 |
| March 04, 2024 | 2.055 |
| March 01, 2024 | 2.074 |
| February 29, 2024 | 2.022 |
| February 28, 2024 | 2.049 |
| February 27, 2024 | 1.942 |
| February 26, 2024 | 1.926 |
| February 23, 2024 | 1.915 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
1.008
Minimum
Mar 23 2020
2.272
Maximum
Dec 29 2021
1.726
Average
1.785
Median
May 25 2021
Price to Book Value Benchmarks
| AC Immune SA | 1.236 |
| CRISPR Therapeutics AG | 2.520 |
| Addex Therapeutics Ltd | 7.014 |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 0.6225 |
Price to Book Value Related Metrics
| PE Ratio | 40.60 |
| PS Ratio | 4.175 |
| PEG Ratio | 0.2109 |
| Price | 79.57 |
| Earnings Yield | 2.46% |
| Market Cap | 39.25B |
| PEGY Ratio | 0.2105 |
| Operating PE Ratio | 38.00 |
| Normalized PE Ratio | 40.60 |